Aptose Biosciences (APTO)
(Real Time Quote from BATS)
$0.48 USD
0.00 (-0.21%)
Updated Aug 15, 2024 03:18 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Aptose Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 52 | 43 | 65 | 56 | 27 |
Income After Depreciation & Amortization | -52 | -43 | -65 | -56 | -27 |
Non-Operating Income | 1 | 1 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -51 | -42 | -65 | -55 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -51 | -42 | -65 | -55 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -51 | -42 | -65 | -55 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -42 | -65 | -55 | -26 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -52 | -43 | -65 | -56 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.76 | 6.20 | 5.97 | 5.50 | 3.37 |
Diluted EPS Before Non-Recurring Items | -7.58 | -6.75 | -10.95 | -10.05 | -7.80 |
Diluted Net EPS (GAAP) | -7.58 | -6.75 | -10.94 | -10.04 | -7.80 |
Fiscal Year end for Aptose Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.34 | 9.77 | 12.13 | 11.69 | 14.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.34 | -9.77 | -12.13 | -11.69 | -14.45 |
Non-Operating Income | 0.09 | 0.12 | 0.17 | 0.23 | 0.32 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.25 | -9.64 | -11.96 | -11.45 | -14.13 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.25 | -9.64 | -11.96 | -11.45 | -14.13 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.25 | -9.64 | -11.96 | -11.45 | -14.13 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 16.76 | 13.13 | 6.76 | 6.50 | 6.23 |
Diluted EPS Before Non-Recurring Items | -0.43 | -0.73 | -1.44 | -1.76 | -2.27 |
Diluted Net EPS (GAAP) | -0.43 | -0.73 | -1.30 | -1.76 | -2.27 |